After the vasopressin antagonist balovaptan flopped in a late-stage clinical trial, Suma Jacob and her colleagues took stock of all the factors that might have complicated the results.

Genetic factors could help explain why the ‘social hormone’ failed to benefit autistic people in a phase 3 clinical trial last year.

Doctors can prescribe it, but evidence that ketamine eases autism traits is still preliminary.

Swiss biotech Stalicla hopes to bring precision medicine to autism. Experts praise efforts to identify autism subgroups, but evidence to support the company’s claims has yet to be seen.

The approach, tested in mice, selectively boosts the expression of the autism-linked gene SCN1A in a subgroup of inhibitory cells.

Strategies to replace or compensate for mutated copies of the TCF4 gene could lead to treatments for this profound form of autism, a new study suggests.

A deactivated form of the gene editor restores UBE3A expression in mice and human neurons without cutting the genome. It may hold promise for future Angelman gene therapies.

Ramping up levels of one isoform of the autism-linked protein reverses traits in model mice, a new study shows.

The experimental compound, called GSK-LSD1, enhances social preferences and reduces repetitive grooming in mice, according to a new study.

Early interventions for autism lack solid data. The source of this problem is murky but may stem from ongoing debates about evidence quality and entrenched conflicts of interest within the field.